Quinidine (µg/mL); Quinidine (µmol/L)
Quinidine, Serum
Test
Method
Kinetic Interaction of Microparticles in Solution (KIMS) Immunoassay
Method Description
The assay is a homogeneous immunoassay based on the principle of measuring changes in scattered light or absorbance, which result when activated microparticles aggregate. The microparticles are coated with quinidine and rapidlyaggregate in the presence of a quinidine antibody solution. When a sample containing quinidine is introduced, the aggregation reaction is partially inhibited, slowing the rate of the aggregation process. Antibody bound to sample drug is no longer available to promote microparticle aggregation, and subsequent particle lattice formation is inhibited. Thus, a classic inhibition curve with respect to quinidine concentration is obtained, with the maximum rate of aggregation at the lowest quinidine concentration. By monitoring the change in scattered light or absorbance, a concentration-dependent curve is obtained.(Package insert: Roche Quinidine reagent, Roche Diagnostic Corp, Indianapolis, IN)
Report Includes
Specimens
Test Location
Mayo Clinical Labs, Minnesota USA
Test Version
30-Sep-2019
Specimen
Specimens
Sample Volume
0.25 mL
Specimen Comment
Avoid gel separator tubes.
Collection & Handling
Handling Information
Separate within 2 hours. Store and send cold or frozen.
Stability
Ambient | 14 days |
---|---|
Refrigerated | 14 days |
Frozen | 14 days |
Test Version
30-Sep-2019
Performance / Interpretation
Method
Kinetic Interaction of Microparticles in Solution (KIMS) Immunoassay
Method Description
The assay is a homogeneous immunoassay based on the principle of measuring changes in scattered light or absorbance, which result when activated microparticles aggregate. The microparticles are coated with quinidine and rapidlyaggregate in the presence of a quinidine antibody solution. When a sample containing quinidine is introduced, the aggregation reaction is partially inhibited, slowing the rate of the aggregation process. Antibody bound to sample drug is no longer available to promote microparticle aggregation, and subsequent particle lattice formation is inhibited. Thus, a classic inhibition curve with respect to quinidine concentration is obtained, with the maximum rate of aggregation at the lowest quinidine concentration. By monitoring the change in scattered light or absorbance, a concentration-dependent curve is obtained.(Package insert: Roche Quinidine reagent, Roche Diagnostic Corp, Indianapolis, IN)
Turnaround Time
7 days
Specimen Retention Time
7 days
Results
Name | Units | Reference Range | Conversion Factor |
---|---|---|---|
Quinidine | µg/mL |
|
µmol/L x 0.325 |
Quinidine | µmol/L |
|
µg/mL x 3.08 |
Test Location
Mayo Clinical Labs, Minnesota USA
Test Version
30-Sep-2019
Interface / Setup
Test Version
30-Sep-2019